SAA1 and uterine cancer: In uterine cancer, SAA1 levels increase as the disease progresses and may be a candidate serum biomarker 16; Non-small cell lung cancer patients who treated with EGF receptor tyrosine kinase inhibitors with elevated serum SAA1 levels have a poor prognosis 17; At the same time, because chronic inflammation is closely related to malignant transformation, SAA1 may affect tumorigenesis and metastasis.